Neurophth
Dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.
Launch date
Employees
Market cap
-
Enterprise valuation
€438m (Public information from Aug 2023)
Wuhan Hubei (HQ)
Authorizing premium user...